Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 10,197 | 9,267 | 73,523 | 25,473 | 2,716 |
| Gross Profit | 10,197 | 9,267 | 73,523 | 25,473 | 2,716 |
| Operating Expenses | 29,258 | 23,249 | 22,991 | 27,407 | 15,606 |
| Operating Income | -19,061 | -13,982 | 50,532 | -1,934 | -12,890 |
| Other Income | 1,199 | 1,313 | 1,046 | 940 | 976 |
| Pre-tax Income | -17,862 | -12,669 | 51,578 | -994 | -11,914 |
| Income Tax | N/A | N/A | 387 | 2,211 | N/A |
| Net Income Continuous | -17,862 | -12,669 | 51,191 | -3,205 | -11,914 |
| Net Income | $-17,862 | $-12,669 | $51,191 | $-3,205 | $-11,914 |
| EPS Basic Total Ops | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |
| EPS Basic Continuous Ops | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |
| EPS Diluted Total Ops | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |
| EPS Diluted Continuous Ops | -0.33 | -0.24 | 0.97 | -0.06 | -0.23 |
| EPS Diluted Before Non-Recurring Items | -0.33 | -0.24 | 0.96 | N/A | N/A |
| EBITDA(a) | $-19,061 | $-13,982 | $50,570 | $-1,826 | $-12,782 |